10 results
·
33ms
·
Sources: EU EUDAMED, US FDA
Filters
Classification: FDA Class 3
×
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·MagtraceTM and Sentimag(R) Magnetic Locatization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·Magtrace/and Sentimag Magnetic Localization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·Magtrace and Sentimag Magnetic Localization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·MagtraceTM and Sentimag(R) Magnetic Locatization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·MagtraceTM and Sentimag(R) Magnetic Locatization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·MagtraceTM and Sentimag(R) Magnetic Locatization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·MagtraceTM and Sentimag(R) Magnetic Locatization System
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·Magtrace® and Sentimag® Magnetic Locatization System (PUV)
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·Magtrace® and Sentimag® Magnetic Locatization System (PUV)
Lymph Node Location System During Sentinel Biopsy Procedure
FDA Pre-Market Approval
FDA Class 3
·Magtrace and Sentimag Magnetic Locatization System (PUV)